Introduction
The purpose of antisense (AS) therapy is to inhibit gene expression and prevent protein production from a targeted gene.
1 Oligodeoxynucleotides (ODNs) are usually prepared with a nuclease resistant derivatization, such as phosphorothioate (PT-ODNs, Figure 1 ) enabling better in vivo activity. However, non-specific oligonucleotide sequences have also demonstrated unexpected potent activity. 2 Moreover, a major problem encountered with the therapeutic use of ODNs is the low cellular permeability due to its large molecular size and high charge density. ODNs have been shown to be taken up to some extent by cells via an energy-dependent endocytosis. 3 To improve cellular delivery of ODNs, several methods employed in DNA delivery have been used such as liposomes, viral vectors and receptor-mediated endocytosis. 4 ODNs adsorbed on to polyalkylcyanoacrylate nanoparticles have been demonstrated to enhance stability against nucleases. However, the problems of efficient cellular delivery, lysosomal degradation and lack of specificity are serious obstacles in therapeutic use.
We hypothesized that effective and safe antisense permeability could be achieved by polymeric nanoparticles Gene Therapy coronary angioplasty (about 35-40%) is restenosis. 10 The migration and proliferation of medial vascular smooth muscle cells (SMC) are thought to be the main components in neointimal formation. 11 Signal transduction through the platelet-derived growth factor (PDGF) receptor system is implicated in the process of post-angioplasty restenosis. A sustained inhibition of this pathway is a promising strategy, which has gained considerable research attention. [12] [13] [14] [15] [16] [17] [18] [19] AS-ODNs have been utilized in an attempt to inhibit growth regulatory or cell-cycle genes (c-myb, c-myc, PCNA, cdc2, and cdk2) of SMC. 16, 20 However, all the ASODNs used were fully phosphorothioated analogs. Although fully phosphorothioated ODNs have increased stability and nuclease resistance, they display high affinity for various cellular proteins, resulting in nonspecific effects. Furthermore, high concentrations of phosphorothioated oligodeoxynucleotides (PT-ODNs) inhibit DNA polymerases and RNase H, which may render them ineffective as antisense agents. 2 Our objective was to develop and examine a controlled release delivery system for antisense sequences. We utilized the proposed nanoparticulate antisense delivery system to deliver PDGF␤R antisense sequences of PT-ODN to SMCs, and to evaluate their efficacy in inhibiting restenosis. Furthermore, in an attempt to minimize the nonspecific effect of the fully phosphorothioated ODNs sequences, partially phosphorothioated ODN sequences have been designed and examined. The antisense sequence used and the nanoparticulate PDGF␤R antisense approach are being reported for the first time.
effect of the naked AS sequence and the AS-NP (nanoparticles) was observed in the rat carotid in vivo model. The extent of mean neointimal formation 14 days after injection of AS-NP, measured as a percentage of luminal sten

Results
Encapsulation
The features of PT-ODN nanoparticles preparation are summarized in Table 1 . A relatively high encapsulation efficiency (amount entrapped) of 81% was achieved. Addition of calcium chloride to the PVA phase resulted in higher encapsulation of the negatively charged PT-ODN.
Size, morphology, and distribution of PT-ODN among the NPs
The size distribution of the particles formed are summarized in Table 2 . All particles formed were in the nanorange (approximately 300 nm). The addition of mannitol before lyophilization resulted in a 100 nm decrease in the final particle size (438 ± 124 and 324 ± 104, without and with mannitol, respectively).
The NPs had a spherical morphology as shown in the TEM micrographs (Figure 2 ). No differences were found between blank and loaded NPs. Table 1 Features of PT-ODN NP preparation
ODN-NP
Initial loading (w/w %) 1.7 Amount in exterior phase (% of initial)
18.2 ± 1.0 Amount entrapped (% of initial) 81.1 ± 4.8 Final loading (w/w %)
1.4
Mean ± s.e.m., n = 6. Labeling of the PT-ODN with the fluorescence probe, FITC, showed a fluorescence signal in over 90% of the particles (Figure 3) .
In vitro release
The sustained release of the PT-ODN from the NP is shown in Figure 4 . About 80% of the initial amount of the PT-ODN was released over 1 month, with a burst effect of about 13% release after 1 day.
Cellular uptake
NPs loaded with FITC-labeled ODNs were shown to internalize and accumulate at the cytoplasm area of the transfected SMC ( Figure 5 ). Blank-NP exhibited very low fluorescence, determined as background for further analysis. Naked FITC-labled ODNs showed low fluorescence at the 2, 5 and 24 h time points (Figure 5a ). Confocal cross-section images of SMC 24 h following delivery of fluorescent (FITC)-labeled ODN encapsulated in NPs are presented in Figure 5b . Confocal cross-sections verified cell internalization (green color, right side), and cytoplasmic localization of the ODNs.
Inhibition of SMC proliferation
The inhibition of SMC proliferation following administration of fully PT-ODNs (II-S) in comparison to partially PT-ODNs (II) is summarized in Table 3 . No difference was found in inhibition between antisense and scrambled sequences at the high concentration of 10 M, both for fully and partially PT-ODNs (Table 3) . At the lower concentration of 5 M, application of naked partially PT-ODN AS resulted in 3.5 times higer inhibition than that obtained with the SC sequence (29.62 ± 9.80 versus 8.55 ± 7.22 % for AS (II) and SC (II), respectively). Moreover, there was no difference between AS and SC effects following application of the fully PT-ODN at this concentration (28.22 ± 3.43 versus 24.02 ± 1.46% for AS-S (II-S) and SC-S (II-S), respectively). Using a DNA synthesisbased assay of BrdU incorporation, the inhibitory effect of PT-ODN AS (II) on PDGF-BB-stimulated proliferation can be found with a concentration-dependent inhibition of about 80% at 10 M, while the SC (II) sequence showed only a weak effect (Figure 6a ). When using sequence (I), both AS and SC inhibited DNA synthesis in an unspecific manner (Figure 6b) .
The results of SMC inhibition following treatment with naked AS PT-ODN (II), naked SC PT-ODN (II), and the parallel NPs are summarized in Table 4 . Inhibition of each naked sequence was determined versus the control group, ie cells only, termed as 100% (see Materials and methods). Inhibitory % of ODN-NPs was determined versus blank NPs. The scrambled sequence showed a very small inhibitory effect in comparison to the antisense sequence. Blank NPs had a poor inhibitory effect, and the cell number was similar to the cell only control group (data not shown). Dose response antiproliferative effect was found for ODN-NP at concentrations of 0.5 and 1 M. PT-ODN NPs were more potent than naked PT-ODN in inhibiting SMCs at all the concentrations tested (5.6 ± 5.6, 0.0, and 0.0 versus 13.23 ± 1.86, 32.18 ± 3.01 and 25.08 ± 1.49%, naked ODNs versus ODN-NPs for 0.5, 1 and 2 M, respectively). Following ODN-NP delivery the inhibitiory effect at 2 M did not increase in comparison to the effect observed at 1 M.
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Inhibition of neointimal formation
The extent of mean neointimal formation 14 days after injection of AS-NP, measured as a percentage of luminal stenosis, was 32.21 ± 4.75% in comparison to 54.89 ± 8.84 and 53.84 ± 5.58% in the blank-NP and SC-NP groups, respectively (P Ͻ 0.05, Table 5 ). Similarly, statistically significant reductions of the mean neointima-to-media ratio were found in the AS-NP treated group in comparison to the blank-NP and SC-NP groups (0.96 ± 0.16 versus 2.01 ± 0.43 and 1.63 ± 0.21, respectively, P Ͻ 0.05, Table 5 ).
Treatment with naked AS resulted in inhibition of neointima formation by 3.1-fold in comparison to naked SC treatment (16.76 ± 7.97 compared with 51.85 ± 6.77% stenosis, respectively, P Ͻ 0.05). Similarly, significant reductions of the mean neointima-to-media ratio were found in the naked AS treated group in comparison to the naked SC group (0.46 ± 0.27 versus 1.4 ± 0.17, respectively, P Ͻ 0.05, Table 5 ).
The reduction of both % stenosis and N/M ratio was 3.1-fold in the naked AS treated group and 1.7-fold in the AS-NP treated group, but the differences between the two groups were not statistically significant.
Medial areas were found similar in all groups (P > 0.5, Table 5 ).
Morphometric results obtained by the morphometric analysis of all sections in the slide correlated very well with the data presented above based on averages of the most constricted sections.
Photomicrographs of representative histological sections are shown in Figure 6 . Note the reduction in neointima (N) formation following treatment with the naked
Figure 5 (a) Confocal images of SMCs transfected with fluorescent (FITC)-labeled ODN encapsulated in NPs. Both negative controls (cells only and blank-NP) exhibited very low fluorescence and were determined as background. An overview of uptake and localization is shown after 2, 5 and 24 h in comparison to delivery of the parallel naked sequences. (b) Confocal cross-section images of SMC after 24 h following delivery of fluorescent (FITC)-labeled ODN encapsulated in NP. Confocal cross-sections verified cell internalization (green color, right side). Note the localization of the NPs in the cytoplasm.
AS sequence (Figure 7a ) and AS-NP ( Figure 7b ) in comparison to the control groups.
Discussion
Antisense ODNs represent potential therapeutic agents for inhibition of SMC proliferation and migration. The delivery of antisense sequences is one of the major challenges antisense technology must overcome before it can be a practical alternative therapy. The PLGA-antisense formulation resulted in high encapsulation efficiency of 81% (Table 1) . By adding calcium ions to the formulation the escape of the negatively charged ODNs to the exterior phase was minimized. This resulted in high encapsulated ODN yields, similar to pDNA encapsulation as previously reported by us. 5 The PLGA formulations were found to be in the nanorange (300 nm) size with homogenous size distribution (Table 2 ) and a spherical morphology ( Figure 2 ). Moreover, ODNs were homogeneously distributed in the prepared NPs ( Figure 3 ). In contrast to pDNA, short sonication is safe for use with ODNs. Sonication in comparision to homogenization, is thought to result in a better stabilization of the first and second emulsion and consequently in decreased particle size. The addition of 2% mannitol prevented the increase in particle size following lyophilization ( Table 2 ). The use The effect of the partially phosphorothioated sequences SC/AS (II), was compared with the fully phosphorothioated sequences SC/AS (II-S) at concentrations of 5 and 10 M. Percent inhibition was calculated as (1 Ϫ(average cell number in treated wells/average cell number in control wells)) × 100. Inhibition % at 3 days, 10% FCS stimulation, mean ± s.e.m., n = 3, differences between the groups were not statistically significant. The effect of the partially phosphorothioated ATG 269 sequences SC/AS (II), was compared with the parallel SC/AS (II)-NPs at concentrations of 0.5, 1 and 2 M. Percent inhibition was calculated as (1 Ϫ(average cell number in treated wells/average cell number in control wells)) × 100. Control wells are medium only and blank NPs for the naked and encapsulated sequences, respectively. Inhibition % at 3 days, 5% FCS stimulation, mean ± s.e.m., n = 3.
of mannitol as a cryoprotectant and its ability to decrease the aggregation of particles during freeze drying have previously been reported. 21, 22 PLGA copolymers are among the few synthetic biocompatible biodegradable polymers approved for human
Figure 6 Inhibition of PDGF-BB stimulated rat SMC proliferation by applying naked antisense sequences AS/SC (sequence II) (a) and AS/SC (sequence I) (b) for 24 h. White bars refer to data from unstimulated cells, while grey bars refer to cells stimulated with PDGF-BB (3 ng/ml) for 20 h.
Gene Therapy use. Cleek et al 23 encapsulated ODN (rat tenascin mRNA AS) in PLGA. Although their formulation yielded microparticles (sieved to sizes smaller than 100 m), efficient cellular entry requires submicron formulation. Our work is the first study demonstrating the use of PLGA NPs as carriers for PDGF␤R ODN antisense sequences. Moreover, the specific sequences developed are the exclusive design of our laboratory.
A sustained release profile of PT-ODN from the NPs was exhibited (Figure 4 ) for a period of over 1 month. Furthermore, a relatively low burst effect of about 13% was observed indicating distribution of the PT-ODN both within the inner and external polymer layers. In previous studies, pluronic gel had been used to deliver ODNs [24] [25] [26] [27] and provided a relatively short bolus delivery (Ͻ3 h). For restenosis therapy, a prolonged treatment (at least a few days) is needed. 28, 29 Our controlled release polymeric system offers the advantage of sustained antisense activity and therapy for prolonged time periods.
It was shown that PT-ODN NPs permeated the cells following transfection (Figure 5a and b) . The permeation mechanism to the cells is probably through endocytosis due to the particles' small size and the polymer's negatively charged surface. This is in accord with previous reports on the cell uptake mechanism of PLGA nanospheres. 30 FITC-labeled ODNs were observed in the cells after 2, 5 and 24 h. In contrast, the parallel FITC-labeled naked sequences were poorly taken up by the cells, and at the time point of 24 h no fluorescence was observed. Since the poor cellular uptake of ODN is a major drawback for therapeutic applications, 31 it is of importance that the nanoparticulate polymeric delivery system exhibited significant transfer of the AS sequences into the cells. However, this result should be confirmed in vivo (see below).
Since the effect of PDGF␤R AS ODN has been examined by others (utilizing the EVAc system matrices 16 ), our preliminary investigations employed ODN-NPs. Furthermore, since fully PT-ODN are widely used, we examined the use of partially PT-ODN in order to minimize the non-specific effects of ODNs.
2 When the inhibition of SMC proliferation was evaluated following the administration of fully PT-ODN, no difference was found between the AS and SC sequences, ie no specific effects were observed (Table 3 , AS (II-S) versus SC (II-S)). However, administration of partially PT-ODN resulted in a marked difference between SC and AS sequences at the low concentration of 5 M (Table 3 , AS (II) versus SC (II)), when cell number was assessed with the AS-ODN present for 3 days. Likewise, the higher concentration of 10 M was efficiently active in a intermediate-term BrdU assay (Figure 6a ). There was no increase in the inhibition at a higher concentration following delivery of the AS (II), probably due to a saturation of the effects or an increase in the non-specific effect of the scrambled sequence at this concentration. Based on the above observations, further investigations were carried out using only partially PT-ODN sequences. The potential for an inhibitory effect on SMCs was observed using ODN-NPs (Table 4) . Blank NPs had no deleterious effects on SMCs. ODN-NPs were found to be more potent at concentrations of 0.5, 1 and 2 M in comparison to naked PT-ODN (Table 4 ). It is postulated that an inhibition of PDGF-induced SMC activation by 30-40% actually represents 80-100% of the maximum inhibition that can be achieved by PDGF␤R blockade. In fact, a number of different strategies to inhibit the action of PDGF reduces neointima formation by 50% (reviewed in Ref. 11) .
A significant antirestenotic effect of the naked AS sequence and the AS-NP was observed in the rat carotid in vivo model (Table 5 and Figure 6 ). Blank NPs showed no deleterious effect on the arteries. The AS sequence used was designed in our laboratory and had not been previously reported. In an earlier report on PDGF␤R antisense for suppression of intimal thickening, 16 the initial amount used was 70 times higher in order to achieve an antirestenotic effect. Sirois et al 16 encapsulated antisense ODN of PDGF␤R in EVAc. Although studies with EVAc polymer demonstrated the feasibility and benefits of periadventitial delivery of SMC inhibitors, the best approach is intraluminal delivery, since it is clinically feasible with noninvasive procedures. It is questionable whether the results obtained by the periadventitial approach can be reproduced by stent coating. In addition, it is advantageous to utilize a biodegradable polymer, since longterm implantation of nondegradable material may result in an inflammatory response.
The observed antirestenotic effect was sequence-specific since both naked SC sequence and SC-NP did not show any effects. Naked AS treatment showed a strong trend towards a greater effect than the AS-NP, but this trend did not reach statistical significance. Since the PT-ODN is released from the NPs over a month period (Figure 4) , it is suggested that the dose of PT-ODN delivered was markedly lower in comparison to the naked AS. The advantage of controlled-release NPs at later time points was demonstrated using pDNA-NPs. 5 Future investigations should examine the in vivo antirestenotic effect of ODN-NP at longer periods of time (eg 1 month) in order to validate the proposed advantage of the NP system. There are three more points that could help to explain our in vivo findings. (1) The total amount of AS in the NP was equivalent to the total amount of naked and scrambled AS, but the release from the NP occurs over weeks. Thus, the naked AS treatment was apparently as effective as the NP treatment in the short-term experiment, but the dose delivered by the NP was much lower. This explanation is undermined in light of the in vitro data. In the in vitro studies, PT-ODN NPs were more potent than naked PT-ODN in inhibiting SMCs at all concentrations tested. We do not have a good explanation for the differences between the in vitro and in vivo effects. It could be that (a) naked AS lose activity in the tissue culture more rapidly than in vivo, or (b) NPs release their content more rapidly in vitro than in vivo. (2) The administration mode used in vivo was by 'bathing' the isolated arterial segment for 20 min. However, uptake into the artery is in favor of dissolved material (naked AS) rather than suspended NP. The latter are prone to sedimentation and are not as freely diffusing as naked AS. (3) The therapeutic window is unknown for the treatment of restenosis using the AS approach. It could therefore be that the in vivo effects were obtained at a dose where the effect reached saturation and therefore we did not observe differences between naked AS and encapsulated AS.
The nanomolar range affinity of phosphorothioated ODNs to proteins that contain polyanion binding sites such as PDGF and VEGF (heparin binding proteins) was previously reported. 32 Blocking the binding of these proteins to their natural receptor is a possible mechanism for our results. However, this is questionable since the affinity was shown to be length-dependent, rather than sequence-dependent, 33 and the observed antirestenotic effect was sequence-dependent (the SC sequence had no effect).
Medial areas were found similar in all of the AS, SC and control groups (Table 5) , indicating no effect on medial SMC viability. Therefore, it is assumed that the PDGF␤R antisense ODN inhibited only the proliferation and migration of neointimal SMCs.
Despite numerous efforts during the past 20 years, restenosis following angioplasty is still a prominent problem in interventional cardiology. There is good experimental evidence that inhibition of platelet-derived growth factor-BB within the arterial wall could prevent restenosis. Here, we are exploring a novel strategy for inhibition of PDGF activity.
The delivery system reported here for the first time also makes it possible to control the release rate kinetics, so as to time ODN dosing, and can be suitable in situations when long-term localized gene suppression meets the aims of therapy. 5 In addition, optional targeting can be achieved by linkage of receptor-specific ligands to the polymer. This platform can be used for virtually any antisense sequence of interest for the treatment of various diseases. Future investigations should address the in vivo antirestenotic effect of ODN-NP for a longer period of time in the pig and rabbit restenosis models. Design of the antisense sequences ODN antisense initiation codon was designed complimentary to the initiation codon to block the translation of rat platelet-derived growth factor ␤-receptor (PDGF␤R) mRNA (GeneBank, entry Z14119). ATG initiation sites were predicted using a web site program (www.hri.co.jp/atgpr/ed) to identify potential initiation codons in the cDNA sequences of PDGF␤R gene. The AS-ODN sequences were confirmed for both specificity and lack of any secondary structure. Typically, PT-ODNs sequences were 18 bases. Each of the PT-ODNs used had three phosphorothioated linkages at each end. The parallel scrambled (SC) sequences were also designed.
Materials and methods
Reagents
The following antisense sequences were designed: 
Preparation and characterization of antisense nanoparticles (AS-NP) NP preparation
A double emulsion system and the solvent evaporation technique were used to incorporate PT-ODN [AS PT-ODN(II)] in PLGA, in a manner similar to pDNA-NP. 5 Briefly, 200-400 l of TE buffer (10 mM Tris and 1 mM EDTA) containing 800-1200 g of PT-ODN (initial loading of 1.1-1.7 w/w%) were emulsified in 3% PLGA/chloroform solution (2.3 ml) and sonicated over an ice-bath microtip probe sonicator (Microson XL; Misonix, Farmingdale, NY, USA) at 11 W for 30 s. The resulting primary emulsion was added dropwise to a 2% PVA solution (in 25 ml TE) containing 7.5 mM calcium chloride, and sonicated for 1 min forming the double emulsion. Following overnight evaporation at 4°C, the formed particles were collected by ultracentrifugation at 80 000 g (TST28 rotor, Beckman's polyallomer centrifuge tubes, 25 × 89 mm), washed three times with sterile DDW, resuspended in double distilled sterile water containing 2% mannitol, and lyophilized.
The amount of PT-ODN entrapped in the NP was analyzed by dissolving the NP (10 mg) in chloroform (1.5 ml), and extracting the PT-ODN from the polymer solution by repetitive additions of TE buffer (×5, 0.5 ml). The PT-ODN content was determined by fluorescence Olig-reen assay kit (Molecular Probes, Eugene, OR, USA) with excitation at 480 nm and emission at 520 nm, and by UV spectroscopy at = 260 nm.
Size, morphology and in vitro release
Laser light scattering (Coulter N4 submicron particle size analyzer, Luton, UK) and transmission electron microscope (TEM CN12, Philips, Eindhoven, The Netherlands) were used to determine particle size, size distribution and morphology. For laser light scattering, the particles were suspended in sterile DDW, the sample intensity (level of cloudiness) was between 5 × 10 4 to 1 × 10 6 counts/s, and the number average is given. PT-ODNs (5-20 mg) were suspended in TE buffer (1 ml) and incubated at 37°C on a shaker at 100 r.p.m. (Lab Line Instruments, Melrose Park, IL, USA). At different time points, the buffer was separated from the NP by centrifugation and analyzed for the amount of released PT-ODN. At each time point, the NPs were resuspended in fresh medium.
Distribution of PT-ODN among the NPs
Fluorescein isothiocyanate (FITC) labeled PT-ODNs were encapsulated in PLGA. A confocal fluorescence laserscanning microscope was used to detect the PT-ODN and the PNA in the NPs (Axiovert 135M, Zeiss 410, Germany; filter set at 488/512).
Cells culture studies
Reagents used for culturing the cells were obtained from Biological Industries, Beit Haemek, Israel, unless otherwise noted. Rat smooth muscle cells (SMCs) were isolated and cultured from thoracic aortas of either Sabra male rats or Sprague-Dawley female rats weighing 200-300 g by the explant method. 12 Freshly dissected blood vessels from animals killed less than 5 min previously were placed in cold media. The vessels were aseptically cleaned by removing the fat and connective tissue (adventitia) and were cut longitudinally. The lumen side was gently scraped with a scalpel blade to dislodge endothelial cells. The vessel wall was then cut with a scalpel blade into 2-mm 2 explants and the luminal surface gently pressed on fibronectin coated surface (3 g/cm 2 ) of 24-well plates. Fibronectin (Sigma) was used to promote cell adhesion as suggested previously. 34, 35 Explants were left to adhere undisturbed for 1 h and growth media was added. Rat aortic explants were cultured in 15% fetal calf serum (FCS) in DMEM high glucose (4500 mg/l) with penicillin (100 U/ml), streptomycin (0.1 mg/ml), and glutamine (2 mM) supplements in a humidifier incubator at 37°C and 5% CO 2 atmosphere. Explants were left undisturbed for the first week, and media was changed every 2 days from the second week. When the cells growing from the explants reached confluence, explants were aspired and cells were subcultured with 0.25% trypsin and placed in 10 ml dishes with the medium changed every 2 days. The cells beyond the first passage were replated on 24-well plates pretreated with fibronectin at 15 000 cells/well and cultured in DMEM, 10% FCS, 1% glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were used from the first to the fifth passage. Cell identity was confirmed through microscopic observation (characteristic 'hill and valley' growth pattern), and smooth muscle ␣-actin immunocytochemistry (Sigma).
Cellular uptake FITC-labeled AS-NPs were used in order to examine the cellular uptake of the AS sequences. Cells (4.5 × 10 4 /ml) were seeded on a Lab-Tek chambered cover glass system (Nalge Nunc International, Naperville, IL, USA) and incubated for 24 h before transfection. The following experimental groups were utilized to study cell transfection: Blank-NP, naked FITC-PT-ODN (1 M) and corresponding concentrations of FITC-PT-ODN NPs. NPs were suspended in the cell media and added to the cells at a NP to media volume ratio of 1:10. Following incubation for 2, 5 and 24 h, cells were carefully washed with PBS (×3), fixed with absolute methanol for 4 min, washed (×3) with PBS, and mounted with fluorescence microscope mounting media (Sigma). NP localization in the cells was detected by confocal fluorescence microscopy as described above.
Inhibition of smooth muscle cells (SMCs) proliferation
SMCs were explanted from rat aortas and cultured as described above. For proliferation assay, cells were seeded in 24-well plates at a density of 15 000 cells per well (15 000/ml) at day 0. On day 1, the original medium was replaced with a growth arrest medium (DMEM containing 0.1% FCS) in order to bring all the cells to the S1 stage. On day 4, the arrest medium was replaced with full medium (15% FCS) containing naked AS and SC sequences, blank NP, SC-NP, or AS-NP, at various concentrations. Control wells received only medium. On day 7 cells were washed with PBS buffer, SMC were released from the plate by trypsinization, and cell number was determined by means of a Coulter counter. All experiments were done in triplicate. Percent inhibition was calculated as (1 Ϫ(average cell number in treated wells/average cell number in control wells)) × 100.
Inhibition of SMCs proliferation -BrdU incorporation assay
SMCs were isolated from rat aorta and cultured as described above. For proliferation assay cells (passage 4) were seeded and cultured in 96-well plate for 48 h, 2000 cells per well in a final volume of 100 l complete medium, DMEM (Life Technologies) with 10% FCS. Then the original medium was replaced with growth arrest medium (DMEM with 0.1% FCS and 0.1% BSA). Following starvation for 48 h, cells were transfected with various concentrations (1, 3 and 10 M) of ATG-77 and ATG-269 antisense and scrambled sequences and 4 h later stimulated with PDGF-BB (end concentration, 3 ng/ml). After incubation overnight the proliferation was assessed using BrdU Labeling and Detection Kit (Roche Molecular Biomedicals).
Inhibition of neointimal formation -rat injured carotid model
The AS-NPs were examined in vivo in an experimental model for restenosis. 10, 36 The procedures were adapted 12, 13, 28 with some modifications and adjustment for antisense delivery. Animals were obtained from Harlan Laboratories, Israel, and housed in the animal facilities of the Faculty of Medicine, The Hebrew University of Jerusalem, conforming to the standards for care and use of laboratory animals of The Hebrew University of Jerusalem and NIH. The animals were fed standard laboratory chow and tap water ad libitum. All in vivo experi-ments were made under general anesthesia achieved with 80 mg/kg ketamine and 5 mg/kg xylazine (i.p.).
The distal left common and external carotid arteries of male Sabra rats (350-420 g) were exposed through a midline incision in the neck. The left common carotid artery was denuded of endothelium by the intraluminal passage of a 2F balloon catheter (Baxter Healthcare, Deerfield, IL, USA) introduced through the external carotid artery. The catheter was passed three times with the balloon distended sufficiently with saline to generate a slight resistance. For intraluminal delivery, 50 units of heparin (in 0.2 ml saline) were injected through the tail vein before the balloon injury. A 2-cm piece of the 10 PE polyethylene tubing was mounted on the 23-G hypodermic needle. A 1-ml syringe containing AS or SC solution was connected to the needle, and the dead space of the needle and tubing was completely filled. After Fogarty catheter withdrawal, the tip of the tubing was inserted through the preformed orifice in the external carotid artery and advanced an additional 4-5 mm into the common carotid artery. To enable an adequate fixation of the tubing and assure hermetization of the arterial segment an additional suture was placed at the origin of the cannulated common carotid artery near the bifurcation. The isolated arterial segment was then bathed with approximately 50 l naked SC (20 M/50 l saline, 1 nmole) or naked AS solutions, or with suspensions of blank NPs, SC-NP and AS-NPs (similar amount of the naked sequence) during a period of 20 min. The syringe and the tubing were then withdrawn, and the external carotid artery was tied off proximally to the site of the tubing entry. This 'bathing method' mimics to some extent the envisaged clinical setting of using 'seating/oozing balloons' or coated stents.
All animals were killed 14 days after injury by an overdose of ether. Arteries were perfusion-fixed with 150 ml of 4% formaldehyde solution pH 7.4 at 100 mm Hg. The right atrium was dissected and an 18-G catheter connected to the perfusion system was inserted in the left ventricle. The arterial segments were dissected, cut, gently separated and postfixed for at least 48 h in the same fixative solution. The central part of the arterial section was taken for histologic examination. The arterial segments were embedded in paraffin and cut at 8-10 sites 600 m apart, and sections of 6 m were mounted and stained with Verhoeff's elastin stain.
Morphometric analysis
Two types of slide evaluation were employed. In the first approach, every slide was studied microscopically by an investigator blinded to the origin of the slide. A single section in every slide, showing the maximal degree of neointimal formation, was chosen. Then a computerized morphometric analysis of the chosen section was performed using dedicated imaging system (Olympus BX40 microscope equipped with the Sony 3 CCD video camera and interfaced with the Power Macintosh computer running the Scion Image 1.62 software). In the second method, assessment was based on morphometric analysis of all sections in the slide (typically 8 to 10). The directly measured values, as well as calculated indices were then averaged for all assessed sections in the slide. The latter method provides a more accurate estimation of the vessel obstruction, since it takes into account the degree of the arterial patency at several sites along the injured segment. The former approach has the advantage of better Gene Therapy clinical relevance since in human restenosis eventual blood flow through the diseased coronary artery is determined by the status of the most occluded 'bottle neck' site. Generally, morphometric results obtained by both methods of calculation correlated well and both are reported. The presented results in this work were calculated from the maximal degree of neointimal formation slide section of each artery.
The residual lumen, the area bounded by the internal elastic lumina (original lumen), and the area circumscribed by the external elastic lamina ('total arterial area') were measured directly. The degree of neointimal thickening was expressed as the ratio between the area of the neointima and the original lumen (percent stenosis) and as the ratio between the neointimal area and the area of the media. The medial area, an indirect index of SMC viability, was determined as the difference between the total arterial area and the original luminal area.
Statistics
Results were expressed as mean ± s.e.m. Statistical differences between groups in the in vitro experiments were assessed by the Kruskal-Wallis nonparametric test, using the InStat software. When required, this test was followed by the Dunn's multiple comparisons post hoc test (P Ͻ 0.05 was termed significant). Differences between AS to SC groups in the experiment assessing antirestenotic activity were termed significant by the unpaired Student's t test at P Ͻ 0.05, using the InStat software.
